Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Choreo LLC

Choreo LLC reduced its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,587 shares of the biotechnology company’s stock after selling 535 shares during the quarter. Choreo LLC’s holdings in Corcept Therapeutics were worth $233,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $25,000. USA Financial Formulas bought a new stake in Corcept Therapeutics during the fourth quarter valued at $54,000. KBC Group NV raised its holdings in shares of Corcept Therapeutics by 21.3% during the third quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 496 shares during the period. GAMMA Investing LLC lifted its position in shares of Corcept Therapeutics by 20.3% in the 4th quarter. GAMMA Investing LLC now owns 2,996 shares of the biotechnology company’s stock worth $151,000 after buying an additional 506 shares during the last quarter. Finally, Ballentine Partners LLC acquired a new position in shares of Corcept Therapeutics in the 4th quarter valued at about $200,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $72.72 on Friday. The business has a 50 day simple moving average of $57.97 and a 200 day simple moving average of $49.31. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The firm has a market capitalization of $7.62 billion, a price-to-earnings ratio of 57.71 and a beta of 0.58. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $74.61.

Insider Transactions at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $68.08, for a total transaction of $149,776.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Joseph Douglas Lyon sold 1,411 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total value of $80,031.92. Following the completion of the sale, the insider now owns 8,494 shares of the company’s stock, valued at $481,779.68. This trade represents a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,011 shares of company stock valued at $1,479,608. 20.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Corcept Therapeutics in a research report on Friday, February 7th. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Finally, Canaccord Genuity Group increased their target price on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $88.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.